For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Molina Healthcare (MOH) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Molina Healthcare is one of 844 companies in the Medical group. The Medical group currently sits at #2 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. MOH is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for MOH's full-year earnings has moved 10.56% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, MOH has gained about 12.82% so far this year. In comparison, Medical companies have returned an average of 1.65%. As we can see, Molina Healthcare is performing better than its sector in the calendar year.
To break things down more, MOH belongs to the Medical - HMOs industry, a group that includes 11 individual companies and currently sits at #14 in the Zacks Industry Rank. On average, this group has lost an average of 1.38% so far this year, meaning that MOH is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track MOH. The stock will be looking to continue its solid performance.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Molina Healthcare, Inc (MOH) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research